NCT03340597View on ClinicalTrials.gov

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

April 13, 2018

Study Completion Date

April 13, 2018

Conditions

Invasive Aspergillosis

Interventions

DRUG

F901318

F901318 tablet

Trial Locations (1)

Unknown

Covance Clinical Research Unit, Leeds

Sponsors

Lead Sponsor

F2G Biotech GmbH

Collaborators (1)

All Listed Sponsors

collaborator

Covance

INDUSTRY

lead

F2G Biotech GmbH

INDUSTRY